Zobrazeno 1 - 10
of 243
pro vyhledávání: '"Elbasvir, Grazoprevir"'
Autor:
Jean‐Pierre Bronowicki, Patrick Miailhes, Bertrand Hanslik, Denis Ouzan, Dominique Larrey, Ghassan Riachi, Régine Truchi, Vincent Jouannaud, Dan Pospait, Armand Abergel, Xavier Causse, Stéphanie Perot, Jérémy Skrzypski, Astrid De Hautecloque, Axelle Spampinato, Philippe Mariot, Philippe Sogni, the Zephyr Study group
Publikováno v:
Health Science Reports, Vol 6, Iss 1, Pp n/a-n/a (2023)
Abstract Background and Aim The efficacy and safety profiles of elbasvir–grazoprevir (EBR/GZR) has been established in more than 10 clinical trials. However, the characteristics of patients treated in routine clinical practice may differ. The prese
Externí odkaz:
https://doaj.org/article/ee9c3ea9dabe43cda866ce4d40cbfb40
Autor:
Ahmad AlEid, Areej Al Balkhi, Adel Qutub, Shahem Abbarh, Abed AlLehibi, Abdullah Almtawa, Nawwaf Al Otaibi, Ahmed AlGhamdi, Adel AlGhamdi, Abdulrahman Alamr, Shameem Ahmad, Khalid Al Sayari, Bashaar Al Ibrahim, Abdullah AlKhathlan
Publikováno v:
The Saudi Journal of Gastroenterology, Vol 28, Iss 3, Pp 225-232 (2022)
Background: Cost, adverse events, and long treatment duration can be significant obstacles in treating hepatitis C virus (HCV)-infected individuals. Shortening the treatment regimen can minimize these barriers, thereby enhancing adherence and increas
Externí odkaz:
https://doaj.org/article/00e74c12f7984cbeacf30facf4566a56
Publikováno v:
Frontiers in Public Health, Vol 10 (2022)
ObjectiveThis study aims to systematically review recent economic evaluations of elbasvir/grazoprevir (EBR/GZR) for chronic hepatitis C (CHC), to critically appraise the reporting quality and to summarize the results.MethodsA literature search was un
Externí odkaz:
https://doaj.org/article/bd95293d7c414096b3c1d20355ef0b5a
Publikováno v:
Clinical Case Reports, Vol 10, Iss 3, Pp n/a-n/a (2022)
Abstract Extrahepatic manifestations of chronic hepatitis C virus (HCV) infection frequently involve the skin. Here, we report the case of a woman, who experienced a psoriasis exacerbation on DAA treatment, which lead to psoriasis resolution upon HCV
Externí odkaz:
https://doaj.org/article/8b2c48f8ae2d47788f3c78aff759eaae
Publikováno v:
Journal of the Formosan Medical Association, Vol 119, Iss 5, Pp 933-940 (2020)
Background/Purpose: The assessment of drug–drug interaction (DDI) is important not only for safety but also for maintaining the efficacy of direct acting antivirals in chronic hepatitis C (CHC). This study aims to evaluate DDI before and during elb
Externí odkaz:
https://doaj.org/article/18093c28cc9a41b09ed20d122f1fb5df
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Objectives: Baseline presence of nonstructural protein 5A (NS5A) resistance-associated variants can attenuate the efficacy of new direct-acting antivirals. A potential method to attain the higher efficacy would be to screen for NS5A polymorphisms pri
Externí odkaz:
https://doaj.org/article/241759756a7641e8bb76108b2c22c0ef
Autor:
Eun Sun Jang, Kyung-Ah Kim, Young Seok Kim, In Hee Kim, Byung Seok Lee, Youn Jae Lee, Woo Jin Chung, Sook-Hyang Jeong
Publikováno v:
The Korean Journal of Internal Medicine, Vol 36, Iss Suppl 1, Pp S1-S8 (2021)
Background/Aim This study aimed to establish the real-world effectiveness and safety of grazoprevir/elbasvir (EBR/GZR) therapy in South Korea. Methods A total of 242 patients with chronic hepatitis C virus (HCV) genotype 1 or 4 infection who started
Externí odkaz:
https://doaj.org/article/74b97b8ab4894622b0d39d7af55e427e
Autor:
Kazuo Tarao, Akira Sato
Publikováno v:
Case Reports in Gastroenterology, Vol 11, Iss 3, Pp 736-741 (2017)
Oral direct-acting antivirals comprise the main therapy for hepatitis C virus (HCV)-associated liver disease in Japan. Daclatasvir/asunaprevir is the primary agent and sofosbuvir/ledipasvir is the secondary agent for HCV genotype 1b. Ombitasvir/parit
Externí odkaz:
https://doaj.org/article/f36ad59d6e4740abb0fb95693e302403
Autor:
Woo Jin Chung, In Hee Kim, Eun Sun Jang, Young Seok Kim, Byung Seok Lee, Kyung-Ah Kim, Sook Hyang Jeong, Youn Jae Lee
Publikováno v:
The Korean Journal of Internal Medicine
The Korean Journal of Internal Medicine, Vol 36, Iss Suppl 1, Pp S1-S8 (2021)
The Korean Journal of Internal Medicine, Vol 36, Iss Suppl 1, Pp S1-S8 (2021)
Background/Aim: This study aimed to establish the real-world effectiveness and safety of grazoprevir/elbasvir (EBR/GZR) therapy in South Korea. Methods: A total of 242 patients with chronic hepatitis C virus (HCV) genotype 1 or 4 infection who starte
Autor:
Kuo-Chih Tseng, Chun-Jen Liu, Ching-Chu Lo, Ming-Lung Yu, Chun-Yen Lin, I-Hao Tseng, Cheng Yuan Peng, Pin-Nan Cheng, Chi-Yi Chen, Chun-Che Lin
Publikováno v:
Journal of Microbiology, Immunology and Infection, Vol 54, Iss 4, Pp 588-595 (2021)
Background & aims: Treatment of hepatitis C virus (HCV) by elbasvir/grazoprevir (EBR/GZR) was found to be efficacious and well tolerated in clinical trials. This study aimed to evaluate the effectiveness and tolerability of EBR/GZR in the treatment o